Related Experiment Videos
Protective effect of SPR-901 (RBS) on the decrease of peripheral leukocyte number in 5-fluorouracil-treated mice
H Miyazaki1, Y Yoshikai, M Tanaka
1Department of Immunology, Kyushu University, Fukuoka, Japan.
International Journal of Immunopharmacology
|January 1, 1992
Summary
SPR-901 mitigates 5-Fluorouracil (5-FU)-induced leukopenia by enhancing bone marrow cell recovery and increasing IL-6 levels. This compound improves survival rates in mice undergoing chemotherapy.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- 5-Fluorouracil (5-FU) chemotherapy can cause leukopenia, a significant challenge in cancer treatment.
- Leukopenia, a decrease in white blood cells, impairs the immune system during cancer therapy.
Purpose of the Study:
- To investigate the effects of SPR-901 on 5-FU-induced leukopenia.
- To determine SPR-901's impact on bone marrow cell proliferation and cytokine levels.
Main Methods:
- Mice were treated with 5-FU and orally administered SPR-901.
- Peripheral leukocyte counts, bone marrow cell proliferation (in response to GM-CSF and G-CSF), and serum IL-6 levels were measured.
- Survival rates were assessed in mice treated with 5-FU alone versus 5-FU combined with SPR-901.
Main Results:
- SPR-901 administration partially prevented the decrease in peripheral leukocytes caused by 5-FU.
- 5-FU suppressed bone marrow cell proliferation, which was enhanced by SPR-901.
- SPR-901 increased serum IL-6 levels in 5-FU-treated mice.
- Combination therapy with SPR-901 significantly improved survival rates compared to 5-FU alone.
Conclusions:
- SPR-901 may modulate macrophage activity, leading to increased production of cytokines like IL-6.
- IL-6, potentially induced by SPR-901-activated macrophages, may synergize with GM-CSF to support early bone marrow progenitor development.
- SPR-901 shows potential as an adjunct therapy to mitigate 5-FU-induced leukopenia and improve treatment outcomes.